AstraZeneca welcomes US government’s announcement to purchase additional 500,000 doses of Evusheld
Evusheld has Emergency Use Authorisation (EUA) for pre-exposure prophylaxis (prevention) of COVID-19.
January 14, 2022
by ExpressPharma
Evusheld to prevent Covid-19: There won't be nearly enough for Americans who are eligible
The US government has only contracted for enough doses of AstraZeneca's Evusheld to cover less than one-tenth the number of people who are eligible for it, reported CNN.
December 27, 2021
by FirstWordPharma
Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralising activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data.
December 20, 2021
by WorldPharmaNews
Evusheld Long-Acting Antibody Combination Retains Neutralizing Activity Against Omicron Variant in Independent FDA Study
AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data.
December 17, 2021
by AmericanPharmaceuticalReview
FDA Issues Emergency Use Authorization for AstraZeneca’s EVUSHELD™ (tixagevimab co-packaged with cilgavimab), the First Antibody Therapy Authorized in the U.S. for Pre-Exposure Prophylaxis of COVID-19
Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the development of the nonproprietary names tixagevimab...
December 13, 2021
by prnewswire
Evusheld (Formerly AZD7442) Long-Acting Antibody Combination Authorized For Emergency Use In The US For Prevention of COVID-19
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected...
December 10, 2021
by AmericanPharmaceuticalReview